Mark A. Munger, PharmD, FCCP, FACC, FHFSA

Commentary

New Research: A Physiological Link Between Hypertension and Diabetes

02/08/2022

Mark A. Munger , PharmD, FCCP, FACC, FHFSA;

Mark Munger, PharmD, FCCP, FACC, reviews new research and considers whether existing or new agents could be used to target both hypertension and diabetes.

Mark Munger, PharmD, FCCP, FACC,...

02/08/2022

Pharmacy Learning Network

Commentary

Suboptimal Heart Health in the United States: Concerns and Solutions

08/10/2022

Mark A. Munger , PharmD, FCCP, FACC, FHFSA;

Citing data on sleep disorders, weight gain, and more, Dr Munger calls for greater attention to improving the US population's cardiovascular health.

Citing data on sleep disorders,...

08/10/2022

Pharmacy Learning Network

Commentary

Healthy Sleep Patterns Reduce the Risk of Cardiovascular Disease

10/14/2021

Mark A. Munger , PharmD, FCCP, FACC, FHFSA;

Mark Munger, PharmD, reviews research that showed a healthy sleep pattern lowers the risk of atrial fibrillation and bradyarrhythmias.

Mark Munger, PharmD, reviews...

10/14/2021

Pharmacy Learning Network

Commentary

Important Changes for Community Pharmacist Practice: Focus on Central Fill Centers

08/17/2023

Mark A. Munger , PharmD, FCCP, FACC, FHFSA;

Dr Munger examines the future of community pharmacy through the expansion of Walgreens and Village Medical primary care practices, exploring how implementing automated fulfillment centers can alleviate prescription-filling pressure and enable...

Dr Munger examines the future of...

08/17/2023

Pharmacy Learning Network

Commentary

Empagliflozin Efficacious, Safe for Acute Heart Failure

03/30/2022

Mark A. Munger , PharmD, FCCP, FACC, FHFSA;

Dr Munger shares new findings on empagliflozin's efficacy in patients with acute heart failure and predicts how these data will impact clinical practice.

Dr Munger shares new findings on...

03/30/2022

Pharmacy Learning Network

Commentary

A Polypill as Secondary Cardiovascular Prevention

09/01/2022

Mark A. Munger , PharmD, FCCP, FACC, FHFSA;

Mark Munger, PharmD, University of Utah, reviews data demonstrating the benefits of a polypill strategy to simplify treatment and improve adherence among adults at risk for cardiovascular disease.

Mark Munger, PharmD, University...

09/01/2022

Pharmacy Learning Network

Commentary

Holding the FDA to Scientific Standards

10/21/2021

Mark A. Munger , PharmD, FCCP, FACC, FHFSA;

“The FDA is a critical component of the drug approval process throughout the US,” says Mark Munger, PharmD. “Having this prestigious body use sound scientific methods and standards for approvals would teach all of us how science should be...

“The FDA is a critical component...

10/21/2021

Pharmacy Learning Network

Commentary

Living With Obesity in 2023: Diet and Exercise, Surgery, or Drug Therapy?

08/23/2023

Mark A. Munger , PharmD, FCCP, FACC, FHFSA;

Today, individuals facing obesity possess a broader range of treatment avenues than ever. However, pharmacists must engage in comprehensive discussions with patients, outlining each treatment path's potential advantages and drawbacks. Read...

Today, individuals facing...

08/23/2023

Pharmacy Learning Network

Commentary

A Calcium Channel Blocker With an Exciting New Indication

04/11/2022

Mark A. Munger , PharmD, FCCP, FACC, FHFSA;

Dr Munger reviews new data showing a calcium channel blocker delayed disease progression and lowered insulin requirements in patients with type 1 diabetes.

Dr Munger reviews new data...

04/11/2022

Pharmacy Learning Network

Commentary

Statins and Exercise: A Paradox

12/11/2013

Mark A. Munger , PharmD, FCCP, FACC, FHFSA;

The newest AHA/ACC Guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults include a recommendation for primary prevention with statins. This recommendation could mean that in as many as 1...

The newest AHA/ACC Guidelines on...

12/11/2013

Pharmacy Learning Network